Aliskiren: Phase III data

Data from 458 evaluable patients in the double-blind, international Phase III AQUARIUS trial showed that once-daily 300 mg aliskiren given for >=72 weeks missed the primary endpoint of reducing the progression of coronary atherosclerosis, defined by

Read the full 361 word article

How to gain access

Continue reading with a
two-week free trial.